History and development of incretin effect:the evidence and promise of incretin-based therapies in the clinical practice

VernacularTitle:肠促胰素效应的发现及其临床应用展望
Author: Tianpei HONG ¹ ; Qing TIAN ; Jin YANG
Author Information

1. 100191,北京大学第三医院内分泌科
Keywords: Incretin; Glucagon-like peptide-1; Diabetes mellitus,type 2
From: Chinese Journal of Endocrinology and Metabolism 2018;34(8):629-633
CountryChina
Language:Chinese
Abstract: The discovery and development of incretin effect has changed the landscape of diabetes treatment over past decades. Nowadays, incretin-based agents, such as glucagon-like peptide-1 ( GLP-1) receptor agonists and dipeptidyl peptidase-4 ( DPP-4) inhibitors have been wildly used in the therapy of type 2 diabetes. These agents show the beneficial effects on the multiple pathophysiological defects of type 2 diabetes, and provide a safe approach for achieving glycemic control with low risk of hypoglycemia and weight gain. Moreover, incretin-based therapies are still in development. Novel incretin-related therapies, such as fixed-dose combinations of GLP-1 receptor agonists and basal insulins, oral GLP-1 receptor agonists, and GLP-1 secretagogues, will be available in clinical practice in the near future.